Darwin Global Management, Ltd. Allogene Therapeutics, Inc. Transaction History
Darwin Global Management, Ltd.
- $1.44 Billion
- Q1 2025
A detailed history of Darwin Global Management, Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Darwin Global Management, Ltd. holds 10,449,791 shares of ALLO stock, worth $11.4 Million. This represents 1.06% of its overall portfolio holdings.
Number of Shares
10,449,791Holding current value
$11.4 Million% of portfolio
1.06%Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$20.4 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$17.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$13.4 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$12.1 Million5.97% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il10.2MShares$11.1 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $157M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...